Keywords: Type 2 diabetes therapies, China, South Korea, DPP-IV inhibitor prescribing, Decision Resources

Physician and payer perspectives on oral type 2 diabetes therapies in China and South Korea

Article | 04 October 2012

China has the largest prevalent population of type 2 diabetes in the world and an ever-expanding affluent middle class, while South ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in